Analysts’ Recent Ratings Updates for MannKind (MNKD)

A number of research firms have changed their ratings and price targets for MannKind (NASDAQ: MNKD):

• 3/11/2026 – MannKind was downgraded by Zacks Research from “hold” to “strong sell”.
• 3/5/2026 – MannKind had its price target lowered by Wedbush from $10.00 to $8.00. They now have an “outperform” rating on the stock.
• 3/2/2026 – MannKind was downgraded by Weiss Ratings from “hold (c)” to “sell (d+)”.
• 2/28/2026 – MannKind was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/27/2026 – MannKind had its price target lowered by Wells Fargo & Company from $8.00 to $7.00. They now have an “overweight” rating on the stock.
• 2/27/2026 – MannKind had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $3.50 price target on the stock, down from $7.50.
• 2/25/2026 – MannKind had its “buy” rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
• 2/10/2026 – MannKind was downgraded by Zacks Research from “strong-buy” to “hold”.
• 1/26/2026 – MannKind had its “buy” rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
• 1/22/2026 – MannKind had its “hold (c)” rating reaffirmed by Weiss Ratings.

Insider Transactions at MannKind

In related news, insider Stuart A. Tross sold 47,006 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the transaction, the insider owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael Castagna bought 100,000 shares of the stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $2.59 per share, for a total transaction of $259,000.00. Following the acquisition, the chief executive officer directly owned 2,575,911 shares in the company, valued at approximately $6,671,609.49. The trade was a 4.04% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 2.70% of the company’s stock.

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.